Key Highlights
- Impact BioMedical stockholders approved the Zoar Limited Merger at a November 13 special meeting.
- The proposal received 7,713,011 votes for and 2,002 against.
- The filing reports approval only and does not confirm closing.
- DSS reported third-quarter Revenue of $3.6 million, down 44%, and going-concern doubt.
DSS, Inc. (NYSE American:DSS) moved a step closer to reshaping one of its holdings this week. Impact BioMedical Inc., in which DSS is the majority shareholder, filed an 8-K signed November 17, 2026 reporting that its stockholders approved a merger and share exchange agreement with Zoar Limited at a November 13 special meeting. For a company facing going-concern doubts and a shrinking operating business, the transaction could influence how investors view DSS's portfolio of interests, although the financial effect on DSS has not been detailed publicly.
Latest Company Context
According to Impact's 8-K, the merger proposal received 7,713,011 votes for and 2,002 against, with about 89% of shares outstanding represented. The filing reports approval only and does not confirm closing. Earlier, on November 2, DSS announced that the SEC had declared the related Form F-4 registration statement effective on October 23; the combined company, Zoar Limited, is expected to list on NYSE American under the ticker "ZOAR," subject to listing approval.
DSS's own third-quarter results, as summarized by market data from its 10-Q, showed revenue of $3.6 million, down 44% year over year, with the product packaging segment posting a gross loss. Operating cash use narrowed to $3.5 million for the nine months from $6.9 million a year earlier, while one customer accounted for 28% of consolidated revenue. Cash was $3.3 million at September 30, and management again cited substantial doubt about the company's ability to continue as a going concern.
Key Business and index Drivers
DSS operates as a Holding Company with interests spanning packaging, securities-related businesses, biotechnology and other investments. The Impact transaction matters because it could change the form of DSS's biotech exposure, potentially from a controlling stake in Impact to an interest in a larger NYSE American-listed company. Neither the release nor the 8-K specified exchange ratios, DSS's resulting ownership or any cash proceeds, so the economic effect remains unclear.
DSS also holds an equity-method stake of about 44.66% in True Partners, carried at roughly $11.4 million, which recorded an $869,000 share of losses over nine months. Meanwhile, core operations remain under pressure: packaging revenue fell 32% in the third quarter, which management attributed to lower orders and onboarding delays for new customers now expected in 2027. A past-due LifeCare obligation of about $39.1 million, negative Working Capital of roughly $42.8 million and unresolved material weaknesses in internal controls add to the risk profile.
What Investors Should Watch
The next milestone is closing of the Zoar transaction, which still depends on NYSE American listing approval and other conditions; the parties have said there is no assurance of a specific timetable, though DSS's quarterly filing pointed to an expected fourth-quarter 2026 close. Investors may watch for disclosure of DSS's post-closing stake and how it will be accounted for. Progress on the LifeCare Loan default, any refinancing or asset sales, and whether new packaging customers begin ordering in 2027 could also shape the outlook. The company's annual report, expected in early 2027, may update the going-concern assessment and the status of control remediation. Dilution is another consideration: market data noted roughly 53 million associated warrants against about 10 million common shares outstanding.
Subsidiary Deal Still Unquantified
Stockholder approval at Impact BioMedical removes one hurdle in a transaction that could alter DSS's biotech holdings, but its value to DSS shareholders has not yet been quantified. The parent company's limited cash, defaulted Debt and weak packaging results remain central considerations. Further disclosures on deal terms and closing could help clarify whether the merger meaningfully changes DSS's financial position or simply reshapes how one of its investments is held.






Please wait processing your request...